Progyny Chief Financial Officer Mark Livingston sold 8,275 shares of common stock in an open-market transaction on May 20, 2026, at $25.50 per share, for a total value of $211,000. The sale represented 9.47% of his direct holdings, leaving him with 79,063 shares worth approximately $2.03 million based on that day's closing price. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, and no indirect or derivative holdings were affected. Progyny, which provides fertility and family-building benefits, reported trailing-twelve-month revenue of $1.29 billion and net income of $67.69 million, and has projected 2026 revenue growth of 6% to 9%, or 10% to 13% excluding a lost major client.
Progyny IncCFO sold 8,275 shares under a pre-arranged plan, representing 9.47% of his direct holdings, which may signal insider sentiment.